RANZCOG ASM 2024
Breakfast and Lunch Masterclasses
Breakfast Sessions
Prof Neil Johnson will be discussing the clinical trials for the newly available treatment for symptomatic uterine fibroids in New Zealand, Ryeqo. He will delve into the clinical trial results for this oral treatment containing Relugolix, a GnRH antagonist, with add-back therapy (estradiol & norethisterone acetate), including both efficacy and safety data, and longer-term outcomes. This data will be related back to clinical practice and there will be an opportunity for Q&A with the audience.
More information to follow.
Lunch Sessions
Using a case study lens, the session will explore a series of escalating patient concerns to help you understand how to manage patient expectations, complications and complaints (and avoid them happening again). Georgie Haysom, the Head of Education Research and Advocacy at Avant, chats with Ruanne Brell, senior solicitor with our Medico-legal Advisory Service, about some of the common situations that can cause you concern. There will be an opportunity for Q&A with the audience.
